Coupon
Mhc Class I Antigens in Malignant Cells : Immune Escape and Response to Immunotherapy
by Natalia Aptsiauri and Angel Miguel Garcia-Lora and Teresa Cabrera


Overview - Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches.  Read more...

 
In Stock.

This item is Non-Returnable.
FREE Shipping for Club Members
 
> Check In-Store Availability

In-Store pricing may vary

 
 
New & Used Marketplace 6 copies from $55.32
 
 
 

More About Mhc Class I Antigens in Malignant Cells by Natalia Aptsiauri; Angel Miguel Garcia-Lora; Teresa Cabrera
 
 
 
Overview
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. ​


This item is Non-Returnable.

 
Details
  • ISBN-13: 9781461465423
  • ISBN-10: 1461465427
  • Publisher: Springer
  • Publish Date: February 2013
  • Page Count: 51
  • Dimensions: 8.9 x 5.9 x 0.3 inches
  • Shipping Weight: 0.4 pounds

Series: Springerbriefs in Cancer Research #6

Related Categories

Books > Medical > Immunology
Books > Science > Life Sciences - Molecular Biology
Books > Medical > Oncology - General

 
BAM Customer Reviews